CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Hanmi Science Subsidiary Hanmi Pharmaceutical Licenses Fabry Disease Therapy to BioMarin in USD 237.5 Million Deal

By Public Technologies
  • Hanmi Science subsidiary Hanmi Pharmaceutical signed a USD 237.5 million Fabry disease licensing deal with BioMarin on October 29, 2026.
  • The agreement includes USD 35 million upfront, USD 202.5 million in milestone payments, and royalties based on annual net sales.
  • BioMarin receives exclusive worldwide rights to LA-GLA; Hanmi Pharmaceutical and GC retain approval and commercialization rights in South Korea.
  • The long-acting enzyme replacement therapy, also called HM15421, is undergoing Phase 1/2 trials domestically and overseas, with GC jointly developing it.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hanmi Science Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261030800021), on October 30, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk